Published in Acta Oncol on January 01, 2007
High dose rate prostate brachytherapy: an overview of the rationale, experience and emerging applications in the treatment of prostate cancer. Br J Radiol (2012) 0.99
Inhibition of p21-activated kinase 6 (PAK6) increases radiosensitivity of prostate cancer cells. Prostate (2010) 0.97
High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up. J Radiat Res (2013) 0.87
Evolution of advanced technologies in prostate cancer radiotherapy. Nat Rev Urol (2013) 0.84
Prostate cancer magnetic resonance imaging (MRI): multidisciplinary standpoint. Quant Imaging Med Surg (2013) 0.82
HDR brachytherapy of prostate cancer - two years experience in Greater Poland Cancer Centre. J Contemp Brachytherapy (2009) 0.78
High dose rate radiation treatment of experimental intramuscular prostate carcinoma. Int J Radiat Biol (2009) 0.75
[Focal dose escalation in the treatment of prostate cancer : Long-term results of HDR brachytherapy]. Urologe A (2017) 0.75
Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA (2010) 10.97
Effect of low doses of ionising radiation in infancy on cognitive function in adulthood: Swedish population based cohort study. BMJ (2004) 3.67
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol (2013) 2.70
A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys (2010) 2.66
Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys (2010) 2.26
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol (2006) 2.18
Image guidance for precise conformal radiotherapy. Int J Radiat Oncol Biol Phys (2003) 2.09
Spinal cord tolerance for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys (2009) 2.08
Effect of fractionation in stereotactic body radiation therapy using the linear quadratic model. Int J Radiat Oncol Biol Phys (2012) 2.00
EAU guidelines on testicular cancer: 2011 update. Eur Urol (2011) 1.96
Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol (2007) 1.93
High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res (2006) 1.82
Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using Stereotactic Body Radiation Therapy in lung cancer. Acta Oncol (2006) 1.77
Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol (2011) 1.73
Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2010) 1.68
Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol (2009) 1.65
A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. Int J Radiat Oncol Biol Phys (2010) 1.64
Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl (2005) 1.54
Feasibility study of helical tomotherapy for total body or total marrow irradiation. Med Phys (2005) 1.52
Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol (2011) 1.51
Tissue shrinkage after fixation with formalin injection of prostatectomy specimens. Virchows Arch (2006) 1.48
Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: A Swedish multicenter randomized trial with patient-reported outcomes. Acta Oncol (2014) 1.46
Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol (2005) 1.45
A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol (2006) 1.41
Systolic versus diastolic cardiac function variables during epirubicin treatment for breast cancer. Int J Cardiovasc Imaging (2009) 1.38
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population. Ophthalmology (2005) 1.32
Guidelines on testicular cancer. Eur Urol (2005) 1.32
Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol (2004) 1.28
Later outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer. Int J Radiat Oncol Biol Phys (2011) 1.25
Clinical implementation of adaptive helical tomotherapy: a unique approach to image-guided intensity modulated radiotherapy. Technol Cancer Res Treat (2006) 1.21
Non-systematic screening for prostate cancer in Sweden--survey from the National Prostate Cancer Registry. Scand J Urol Nephrol (2003) 1.20
The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival. Scand J Urol Nephrol (2005) 1.20
Reirradiation human spinal cord tolerance for stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys (2010) 1.20
Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2. Scand J Urol Nephrol (2002) 1.14
Satellite-based terrestrial production efficiency modeling. Carbon Balance Manag (2009) 1.11
Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology (2008) 1.07
A pooled analysis of thyroid cancer incidence following radiotherapy for childhood cancer. Radiat Res (2012) 1.03
Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro. Int J Oncol (2010) 1.01
Self-perceived physical, psychologic, and general symptoms in survivors of testicular cancer 3 to 13 years after treatment. Cancer Nurs (2002) 1.01
Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scand J Urol Nephrol Suppl (2005) 1.01
Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group. J Clin Oncol (2011) 0.99
How fast is repopulation of tumor cells during the treatment gap? Int J Radiat Oncol Biol Phys (2002) 0.99
Full-term newborn after repeated ovarian tissue transplants in a patient treated for Ewing sarcoma by sterilizing pelvic irradiation and chemotherapy. Acta Obstet Gynecol Scand (2015) 0.96
A genome-wide association study of men with symptoms of testicular dysgenesis syndrome and its network biology interpretation. J Med Genet (2011) 0.96
System for interstitial photodynamic therapy with online dosimetry: first clinical experiences of prostate cancer. J Biomed Opt (2010) 0.96
Stereotactic body radiation therapy in non-small-cell lung cancer: linking radiobiological modeling and clinical outcome. Am J Clin Oncol (2011) 0.93
Somatostatin effects on the proteome of the LNCaP cell-line. Int J Oncol (2007) 0.90
Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol (2005) 0.90
Proteomic analysis of protein expression in prostate cancer. Anal Quant Cytol Histol (2005) 0.89
Charge-dependent targeting: results in six tumor cell lines. Anticancer Res (2004) 0.89
Experience from long-term monitoring of RAKR ratios in (192)Ir brachytherapy. Radiother Oncol (2008) 0.88
Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer. Anticancer Res (2012) 0.88
Intention to test for prostate cancer. Eur J Cancer (2005) 0.88
Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells. Oncol Rep (2008) 0.87
Late outcomes following hypofractionated conformal radiotherapy vs. standard fractionation for localized prostate cancer: a nonrandomized contemporary comparison. Int J Radiat Oncol Biol Phys (2009) 0.87
On-time mammography screening with a focus on Latinas with low income: a proposed cultural model. Anticancer Res (2008) 0.87
Prostate volume determination: differential volume measurements comparing CT and TRUS. Radiother Oncol (2006) 0.87
Characteristics of response of oral and pharyngeal mucosa in patients receiving chemo-IMRT for head and neck cancer using hypofractionated accelerated radiotherapy. Radiother Oncol (2010) 0.87
Comparison of protein expression in two prostate cancer cell-lines, LNCaP and DU145, after treatment with somatostatin. Oncol Rep (2009) 0.86
Testicular cancer and testicular self-examination: knowledge and attitudes of adolescent Swedish men. Cancer Nurs (2005) 0.86
Association of polymorphisms in genes encoding hormone receptors ESR1, ESR2 and LHCGR with the risk and clinical features of testicular germ cell cancer. Mol Cell Endocrinol (2012) 0.85
Sexual function in men treated for testicular cancer. J Sex Med (2009) 0.85
Bladder cancer-induced skeletal muscle wasting: disclosing the role of mitochondria plasticity. Int J Biochem Cell Biol (2013) 0.84
Acute toxicity after hypofractionated conformal radiotherapy for localized prostate cancer: nonrandomized contemporary comparison with standard fractionation. Int J Radiat Oncol Biol Phys (2008) 0.84
Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)ir brachytherapy: a prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25. Int J Radiat Oncol Biol Phys (2004) 0.83
Differential protein expression in anatomical zones of the prostate. Proteomics (2005) 0.83
Prostasome-derived proteins capable of eliciting an immune response in prostate cancer patients. Int J Cancer (2006) 0.83
Association between polymorphisms in the aryl hydrocarbon receptor repressor gene and disseminated testicular germ cell cancer. Front Endocrinol (Lausanne) (2013) 0.82
Barriers identified by Swedish school nurses in giving information about testicular cancer and testicular self-examination to adolescent males. J Sch Nurs (2005) 0.82
Correlation of protein expression, Gleason score and DNA ploidy in prostate cancer. Proteomics (2006) 0.82
Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation. Int J Radiat Oncol Biol Phys (2006) 0.82
Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines. Scand J Urol Nephrol (2009) 0.82
Dose-response relationship for parathyroid adenoma after exposure to ionizing radiation in infancy. Radiat Res (2002) 0.82
Potential for radiation therapy technology innovations to permit dose escalation for non-small-cell lung cancer. Clin Lung Cancer (2005) 0.81
Prostate cancer cell lines lack amplification: overexpression of HER2. Acta Oncol (2005) 0.81
XAF1 expression and regulatory effects of somatostatin on XAF1 in prostate cancer cells. J Exp Clin Cancer Res (2010) 0.81
Breast cancer risk among Swedish hemangioma patients and possible consequences of radiation-induced genomic instability. Mutat Res (2009) 0.81
Treatment of bone metastasis in prostate cancer: efficacy of a novel polybisphosphonate. Anticancer Res (2011) 0.81
Baicalein inhibits prostate cancer cell growth and metastasis via the caveolin-1/AKT/mTOR pathway. Mol Cell Biochem (2015) 0.81
Atypical stromal hyperplasia of the prostate. Scand J Urol Nephrol (2008) 0.80
Prostate displacement kit: reducing the radiation dose to the rectum. Radiother Oncol (2006) 0.80
Proteomic analysis of soft tissue tumor implants treated with a novel polybisphosphonate. Cancer Genomics Proteomics (2014) 0.80
Accelerated hypofractionation. Int J Radiat Oncol Biol Phys (2005) 0.80
Promising long-term health-related quality of life after high-dose-rate brachytherapy boost for localized prostate cancer. Int J Radiat Oncol Biol Phys (2007) 0.80
Postoperative radiotherapy after prostatectomy--a review. Scand J Urol Nephrol (2003) 0.80